Fresenius Medical Care AG & Co. KGaA

Fresenius Medical Care AG & Co. KGaA

FME.DE

€39.15

Updated: 22/09/2026, 12:04:02

Market Cap
€10.42B
Sector
Healthcare
Industry
Medical - Care Facilities
Country
DE
Stock valuation chart
One-year closing share-price history for FME.DE
Company Profile

Fresenius Medical Care AG & Co. KGaA operates as a premier international provider of comprehensive dialysis services and related care, with a significant presence in Germany, North America, and numerous other countries. The company delivers essential dialysis treatments, laboratory analyses, and diagnostic services through its extensive network of outpatient dialysis clinics. Complementing its clinical offerings, Fresenius provides necessary materials, patient training, ongoing clinical monitoring, follow-up support, and arranges for the delivery of supplies directly to patients' residences. In the United States, Fresenius extends its services to hospitals, offering contract dialysis care for inpatients suffering from end-stage renal disease (ESRD) and those experiencing acute kidney failure. Beyond services, the company is a key player in the development, manufacturing, and global distribution of a broad spectrum of dialysis products. This portfolio includes items such as polysulfone dialyzers, hemodialysis machines, peritoneal dialysis cyclers, peritoneal dialysis solutions, hemodialysis concentrates, specialized solutions and granulates, bloodlines, renal pharmaceuticals, and water treatment systems. Additionally, Fresenius produces non-dialysis products, including those for acute cardiopulmonary conditions and apheresis. The company further enhances its offerings by developing, acquiring, and in-licensing renal pharmaceuticals, ensuring these medications and other vital supplies reach patients at home or in dialysis clinics. It also provides an array of specialized medical services, covering vascular, cardiovascular, and endovascular care, operating vascular care ambulatory surgery centers, and delivering physician nephrology and cardiology services. Fresenius Medical Care distributes its extensive product range to dialysis clinics, hospitals, and specialized treatment centers via multiple avenues, including direct sales, dedicated local sales forces, independent distributors, dealers, and sales agents. As of February 23, 2022, the company managed an impressive 4,171 outpatient dialysis clinics across approximately 150 countries. Fresenius Medical Care AG & Co. KGaA was established in 1996 and is headquartered in Bad Homburg, Germany.

EUR
XETRA
CEO: Helen Giza
Employees: 107,226
https://www.freseniusmedicalcare.com
Asset Summaries
Latest generated summaries for FME.DE

No summaries found.

Detailed business
The latest official filing is available; structured extraction is pending.
FME.DE-geschaeftsbericht-fy2026.pdf7.4 MBapplication/pdfDE

The original document can be viewed now. Detailed facts and exposure relationships will appear after the separate extraction job completes.

Full company information
Latest profile, trading, valuation, and identifier data stored for FME.DE.
Share price
€39.15
Market cap
€10.42B
Exchange
XETRA
Currency
EUR
CEO
Helen Giza
Employees
107,226
IPO date
22/07/1998
Beta
0.9409665
Last dividend
€0.00
Day range
€38.67 – €39.20
52-week range
€34.57 – €47.86
1-day performance
0.77%
1-year performance
13.25%
Current drawdown (1Y)
-18.20%
CIK
N/A
CUSIP
D2734Z107
ISIN
DE0005785802
Created
07/09/2026, 05:15:41
Last update
22/09/2026, 12:04:02

Track Fresenius Medical Care AG & Co. KGaA with an AI analyst

See which prediction-market events move FME.DE, how its filings map to real-world exposure, and what 12 AI strategies are doing with positions like it.

Free forever to follow AlphaBrain’s AI strategies. No card required.

Latest Database News
News linked to FME.DE from your Railway `news_articles` table.

No news found for this symbol.